Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
33.63%
Operating Margin
20.71%
Net Margin
12.21%
Efficiency Metrics
Revenue per Expense Ratio
1.26
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
32.17%
Income Tax Rate
0.00%
EPS
6.6300000000
Balance Sheet Analysis
Current Ratio
0.19
Cash Ratio
0.06
Working Capital
$-7.61B
Debt to Equity
4.68
Debt to Assets
62.99%
Equity Ratio
13.45%
Cash Flow Analysis
Operating Cash Flow Ratio
32.21%
Free Cash Flow Ratio
4.17%
CapEx to Revenue
28.04%
Dividends Paid
No dividends paid
Stock Buybacks
No buybacks
Total Shareholder Returns
No shareholder returns
Cash Position Change
-74.32%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
57.23%
Net Income
180.82%
EPS
180.56%
Operating Income
439.41%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
25.15%
Operating Cash Flow
829.11%
Free Cash Flow
126.03%
Balance Sheet Health
Assets
4.01%
Debt
-7.77%
Book Value per Share
70.11%
Inventory
10.71%
Shareholder Returns
Dividends per Share
0.00%
Shares Outstanding
0.39%
Long Term Trends
3Y Revenue/Share
426.88%
5Y Revenue/Share
20.43%
3Y Dividend/Share
-100.00%
5Y Dividend/Share
-100.00%